In one illustrative NPM1-mutated AML (SLS305), unsupervised clustering revealed different patterns of drug activity, including one with predominant activity on the leukemic bulk with lower efficacy on LSCs and differentiation (“cytotoxic” pattern A), one with predominant activity on the proportion of LSCs (“stemness-specific” pattern B) and one with prominent differentiating activity (pattern C, Fig. 2B). The gene discussed is NPM1; the disease is acute myeloid leukemia.